Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa

BACKGROUND: Dexamethasone and remdesivir have the potential to reduce coronavirus disease 2019 (COVID)–related mortality or recovery time, but their cost-effectiveness in countries with limited intensive care resources is unknown. METHODS: We projected intensive care unit (ICU) needs and capacity fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Youngji, Jamieson, Lise, Edoka, Ijeoma, Long, Lawrence, Silal, Sheetal, Pulliam, Juliet R C, Moultrie, Harry, Sanne, Ian, Meyer-Rath, Gesine, Nichols, Brooke E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928624/
https://www.ncbi.nlm.nih.gov/pubmed/33732750
http://dx.doi.org/10.1093/ofid/ofab040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928624/
https://www.ncbi.nlm.nih.gov/pubmed/33732750
http://dx.doi.org/10.1093/ofid/ofab040

Ejemplares similares